Neurocrine Biosciences (NBIX) Current Assets (2010 - 2026)
Neurocrine Biosciences (NBIX) reported Current Assets of $1.64 billion for Q2 2026, down 6.4% from $1.75 billion a year earlier and down 32.8% from the prior quarter.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Current Assets (2010 - 2026) Analysis & Trends
At the end of FY2025, Neurocrine Biosciences posted Current Assets of $2.52 billion, up 46.3% from FY2024.
- Current Assets has increased for four consecutive years, with a five-year compound annual growth rate of 19.9% (FY2020 to FY2025).
- By year, Current Assets came in at $1.72 billion in FY2024 (+7.3%), $1.61 billion in FY2023 (+10.6%), $1.45 billion in FY2022 (+49.4%) and $972.8 million in FY2021 (-4.3%).
- The Q2 2026 figure ranks as the lowest quarterly Current Assets since Q4 2023.
- Year over year, Current Assets gained in six of the last eight quarters, with growth averaging 15.1%.
- The high point for year-over-year Current Assets in five years was Q4 2022 (growth of 49.4%); the low point was Q3 2021 (a decline of 13.1%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $2.44 billion (Q1 2026), $2.52 billion (Q4 2025) and $2.16 billion (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 59.77 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 33.67 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 36.68 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 27.35 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 27.97 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 34.96 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 13.95 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 41.36 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 12.54 Bn |
| 10 | Neurocrine Biosciences | 14.41 Bn | 10.11 Bn | 935.80 Mn | 1.64 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.64 Bn |
| Mar 31, 2026 | 2.44 Bn |
| Dec 31, 2025 | 2.52 Bn |
| Sep 30, 2025 | 2.16 Bn |
| Jun 30, 2025 | 1.75 Bn |
| Mar 31, 2025 | 1.64 Bn |
| Dec 31, 2024 | 1.72 Bn |
| Sep 30, 2024 | 1.88 Bn |
| Jun 30, 2024 | 1.67 Bn |
| Mar 31, 2024 | 1.80 Bn |
| Dec 31, 2023 | 1.61 Bn |
| Sep 30, 2023 | 1.65 Bn |
| Jun 30, 2023 | 1.50 Bn |
| Mar 31, 2023 | 1.43 Bn |
| Dec 31, 2022 | 1.45 Bn |
| Sep 30, 2022 | 1.21 Bn |
| Jun 30, 2022 | 1.02 Bn |
| Mar 31, 2022 | 1.02 Bn |
| Dec 31, 2021 | 972.80 Mn |
| Sep 30, 2021 | 1.01 Bn |
API Access
Neurocrine Biosciences Current Assets API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=current-assets&ticker=NBIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "current-assets", "ticker": "NBIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=current-assets&ticker=NBIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();